Zobrazeno 1 - 10
of 192
pro vyhledávání: '"Edward M, Wolin"'
Autor:
Matthew H Kulke, Fang-Shu Ou, Donna Niedzwiecki, Lucas Huebner, Pamela Kunz, Hagen F Kennecke, Edward M Wolin, Jennifer A Chan, Eileen M O’Reilly, Jeffrey A Meyerhardt, Alan Venook
Publikováno v:
Endocr Relat Cancer
Treatment with the mTOR inhibitor everolimus improves progression-free survival in pancreatic neuroendocrine tumors, but it is not known if the addition of a VEGF pathway inhibitor to an mTOR inhibitor enhances antitumor activity. We performed a rand
Autor:
Simron Singh, Wieneke Buikhuisen, Jaume Capdevila, Martyn E Caplin, Christian Grohe, Dieter Horsch, Markus Raderer, Diane Reidy-Lagunes, Edward M Wolin, Christelle Pommie, Truong Xuan Mai, Eric Baudin
Publikováno v:
Endocrine Abstracts.
Autor:
Eric P. Krenning, Philippe Ruszniewski, David L. Bushnell, Andrew Eugene Hendifar, Oscar Leeuwenkamp, Paola Santoro, Beth R Chasen, Edward M. Wolin, Per Broberg, Matthew H. Kulke, Ghassan El-Haddad, Kjell Öberg, Martyn Caplin, Jonathan R. Strosberg, Richard P. Baum, Rajaventhan Srirajaskanthan
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol 62, iss 12
Journal of Nuclear Medicine, 62(12), 1712-1718. Society of Nuclear Medicine and Molecular Imaging
Journal of Nuclear Medicine, 62(12), 1712-1718. Society of Nuclear Medicine and Molecular Imaging
We report the impact of 177Lu-DOTATATE treatment on abdominal pain, diarrhea, and flushing, symptoms that patients with advanced midgut neuroendocrine tumors often find burdensome. Methods: All patients enrolled in the international randomized phase
Autor:
Monica Naparst, Naomi Alpert, Michelle K. Kim, Kelly E Diaz, Emanuela Taioli, Elizabeth Kessel, Eugene Ahn, Edward M. Wolin
Publikováno v:
Pancreas. 50:29-36
Objectives The objective of this study was to evaluate racial differences in cancer treatment and survival in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. Methods Using the Surveillance, Epidemiology, and End Results Registry, we i
Autor:
Eva L Alba, Emily A Japp, Gustavo Fernandez-Ranvier, Ketan Badani, Eric Wilck, Munir Ghesani, Andrea Wolf, Edward M Wolin, Virginia Corbett, David Steinmetz, Maria Skamagas, Alice C Levine
Publikováno v:
Journal of the Endocrine Society. 6
Neoplasms that secrete ectopic adrenocorticotropin (ACTH) may cause severe, life-threatening hypercortisolism. These tumors are often difficult to localize and treat, requiring a comprehensive and systematic management plan orchestrated by a multidis
Autor:
Philippe Ruszniewski, Edward M. Wolin, Jarosław B. Ćwikła, Martyn Caplin, Clarinet Investigators, Eva Sedlackova, Marianne Pavel, Alexandria T. Phan, Xuan-Mai Truong Thanh
Publikováno v:
Endocrine
Purpose In the phase III CLARINET study (NCT00353496), lanreotide autogel/depot (lanreotide) significantly improved progression-free survival (PFS) vs placebo in patients with non-functioning intestinal or pancreatic neuroendocrine tumours (NETs). Th
Autor:
Edward M. Wolin, Guido Rindi, Jaume Capdevila, Eva Sedlackova, Guillaume Cadiot, Alexandria T Phan, Philippe Ruszniewski, Jarosław B. Ćwikła, Tal Grenader, Markus Raderer, Xuan-Mai Truong Thanh, Martyn Caplin, Marianne Pavel, Lucy Wall
Publikováno v:
Anti-Cancer Drugs
Grenader, T, Pavel, M E, Ruszniewski, P B, Ćwikła, J, Phan, A T, Raderer, M, Sedláčková, E, Cadiot, G, Wolin, E M, Capdevila, J, Wall, L, Rindi, G, Thanh, X M T, Caplin, M E & CLARINET Study Group 2020, ' Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors ', Anti-Cancer Drugs, vol. 31, no. 3, pp. 216-222 . https://doi.org/10.1097/CAD.0000000000000909
Scientia
Grenader, T, Pavel, M E, Ruszniewski, P B, Ćwikła, J, Phan, A T, Raderer, M, Sedláčková, E, Cadiot, G, Wolin, E M, Capdevila, J, Wall, L, Rindi, G, Thanh, X M T, Caplin, M E & CLARINET Study Group 2020, ' Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors ', Anti-Cancer Drugs, vol. 31, no. 3, pp. 216-222 . https://doi.org/10.1097/CAD.0000000000000909
Scientia
Supervivència lliure de progressió; Tumors neuroendocrins Supervivencia libre de progresión; Tumores neuroendocrinos Progression-free survival; Neuroendocrine tumors Accessible prognostic tools are needed to individualize treatment of neuroendocri
Publikováno v:
Journal of the American College of Surgeons. 233:e177-e178
Autor:
Arnaud Demange, Andrew Eugene Hendifar, Marianne Pavel, James C. Yao, E. Van Cutsem, Martyn Caplin, Enrique Grande, Edward M. Wolin, Philippe Ruszniewski, Ettore Seregni, Jonathan R. Strosberg, E.P. Krenning, Lisa Bodei, Erik Mittra, Hugo Duarte, Sakir Mutevelic, Pamela L. Kunz
Publikováno v:
Annals of Oncology. 32:S911-S912
Autor:
Jonathan R. Strosberg, Ettore Seregni, Sakir Mutevelic, Pamela L. Kunz, Martyn Caplin, E.P. Krenning, Lisa Bodei, Amy Bartalotta, Arnaud Demange, Hugo Duarte, Marianne Pavel, Philippe Ruszniewski, Edward M. Wolin, Erik Mittra, E. Grande Pulido, E. Van Cutsem, James C. Yao, Andrew Eugene Hendifar, Germo Gericke
Publikováno v:
Annals of Oncology. 32:S217-S218